|
Name |
(1R,3Z,6R,7Z,9S,11Z,13R,14S,17R,18S)-6,14-dihydroxy-18-(1H-indol-3-ylmethyl)-7,9,15,16-tetramethyl-19-azatricyclo[11.7.0.01,17]icosa-3,7,11,15-tetraene-2,5,20-trione
|
| Molecular Formula | C32H36N2O5 | |
| IUPAC Name* |
(1R,3Z,6R,7Z,9S,11Z,13R,14S,17R,18S)-6,14-dihydroxy-18-(1H-indol-3-ylmethyl)-7,9,15,16-tetramethyl-19-azatricyclo[11.7.0.01,17]icosa-3,7,11,15-tetraene-2,5,20-trione
|
|
| SMILES |
C[C@H]/1C/C=C\[C@H]2[C@@H](C(=C([C@@H]3[C@@]2(C(=O)/C=C\C(=O)[C@@H](/C(=C1)/C)O)C(=O)N[C@H]3CC4=CNC5=CC=CC=C54)C)C)O
|
|
| InChI |
InChI=1S/C32H36N2O5/c1-17-8-7-10-23-30(38)20(4)19(3)28-25(15-21-16-33-24-11-6-5-9-22(21)24)34-31(39)32(23,28)27(36)13-12-26(35)29(37)18(2)14-17/h5-7,9-14,16-17,23,25,28-30,33,37-38H,8,15H2,1-4H3,(H,34,39)/b10-7-,13-12-,18-14-/t17-,23-,25-,28-,29+,30+,32+/m0/s1
|
|
| InChIKey |
VUEFRYQBOMQOMV-QGODYLGVSA-N
|
|
| Synonyms |
chaetoglobosin B
|
|
| CAS | NA | |
| PubChem CID | 102093916 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 528.6 | ALogp: | 2.6 |
| HBD: | 4 | HBA: | 5 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 120.0 | Aromatic Rings: | 5 |
| Heavy Atoms: | 39 | QED Weighted: | 0.34 |
| Caco-2 Permeability: | -5.02 | MDCK Permeability: | 0.00000851 |
| Pgp-inhibitor: | 0.949 | Pgp-substrate: | 0.991 |
| Human Intestinal Absorption (HIA): | 0.021 | 20% Bioavailability (F20%): | 0.033 |
| 30% Bioavailability (F30%): | 0.112 |
| Blood-Brain-Barrier Penetration (BBB): | 0.181 | Plasma Protein Binding (PPB): | 99.12% |
| Volume Distribution (VD): | 1.073 | Fu: | 1.58% |
| CYP1A2-inhibitor: | 0.076 | CYP1A2-substrate: | 0.5 |
| CYP2C19-inhibitor: | 0.885 | CYP2C19-substrate: | 0.777 |
| CYP2C9-inhibitor: | 0.876 | CYP2C9-substrate: | 0.798 |
| CYP2D6-inhibitor: | 0.23 | CYP2D6-substrate: | 0.23 |
| CYP3A4-inhibitor: | 0.951 | CYP3A4-substrate: | 0.384 |
| Clearance (CL): | 9.937 | Half-life (T1/2): | 0.644 |
| hERG Blockers: | 0.279 | Human Hepatotoxicity (H-HT): | 0.318 |
| Drug-inuced Liver Injury (DILI): | 0.291 | AMES Toxicity: | 0.508 |
| Rat Oral Acute Toxicity: | 0.604 | Maximum Recommended Daily Dose: | 0.939 |
| Skin Sensitization: | 0.843 | Carcinogencity: | 0.072 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.008 |
| Respiratory Toxicity: | 0.941 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002955 | ![]() |
0.815 | D0W7WC | ![]() |
0.257 | ||
| ENC002440 | ![]() |
0.785 | D01TSI | ![]() |
0.255 | ||
| ENC002120 | ![]() |
0.744 | D02DMQ | ![]() |
0.248 | ||
| ENC002443 | ![]() |
0.742 | D0BV3J | ![]() |
0.247 | ||
| ENC004473 | ![]() |
0.722 | D0SP3D | ![]() |
0.242 | ||
| ENC002441 | ![]() |
0.701 | D09NNH | ![]() |
0.242 | ||
| ENC004469 | ![]() |
0.662 | D0V3ZA | ![]() |
0.242 | ||
| ENC002953 | ![]() |
0.636 | D05EJG | ![]() |
0.240 | ||
| ENC002681 | ![]() |
0.636 | D02XIY | ![]() |
0.238 | ||
| ENC002679 | ![]() |
0.634 | D09ZIO | ![]() |
0.230 | ||